Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

BACKGROUND: Outcomes of younger acute myeloid leukaemia patients have moderately improved. Blocking PD-1/PD-L1 pathways enhances anti-leukaemia responses by enabling T-cells in murine models. We hypothesized that adding nivolumab to frontline therapy may decrease the risk of relapse. METHODS: Patien...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Lancet Haematol
Κύριοι συγγραφείς: Ravandi, Farhad, Assi, Rita, Daver, Naval, Benton, Christopher B, Kadia, Tapan, Thompson, Philip A, Borthakur, Gautam, Alvarado, Yesid, Jabbour, Elias J., Konopleva, Marina, Takahashi, Koichi, Kornblau, Steven, DiNardo, Courtney D., Estrov, Zeev, Flores, Wilmer, Basu, Sreyashi, Allison, James, Sharma, Padmanee, Pierce, Sherry, Pike, Allison, Cortes, Jorge E., Garcia-Manero, Guillermo, Kantarjian, Hagop M.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2019
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6778960/
https://ncbi.nlm.nih.gov/pubmed/31400961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(19)30114-0
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια